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not LPS and d-lactates were significantly higher in HD than 
in healthy controls. d-lactates and LPS levels were weakly 
associated with IL6 (R = 0.175; p = 0.03, and R = 0.241; 
p = 0.003). There was a borderline correlation between 
plasma zonulin and serum hsCRP (R = 0.159; p = 0.07), 
but not with IL6, LPS and d-lactates. In multiple regres-
sion, both serum CRP and plasma IL6 variability were 
explained by LPS (β = 0.143; p = 0.08 and β = 0.171; 
p = 0.04, respectively), only.
Conclusion The weak association between plasma d-lactate, 
LPS and IL6 levels indicates that intestinal flora overgrowth 
or increased intestinal permeability contributes very slightly 
to the chronic inflammation development in HD patients.
Keywords Zonulin · Chronic renal failure · 
Haemodialysis · d-Lactate · Inflammation · Intestinal 
permeability
Abstract 
Background Increased permeability of the intestinal wall 
and intestinal dysbiosis may contribute to chronic systemic 
inflammation, one of the causes of accelerated atherosclerosis 
and cardiovascular morbidity and mortality burden in patients 
with chronic kidney disease. The aim of this study was to 
evaluate the association between markers of intestinal perme-
ability and inflammation in haemodialysis (HD) patients.
Methods Plasma concentration of zonulin, haptoglobin, 
TNFα, IL6, d-lactates and bacterial lipopolysaccharides 
(LPS) was assessed in blood samples obtained after over-
night fast before midweek morning HD session in 150 
stable, prevalent HD patients. Daily intake of energy and 
macronutrients was assessed on the basis of a food fre-
quency questionnaire.
Results Serum hsCRP level was increased in over 70% of 
patients. Plasma levels of zonulin [11.6 (10.9–12.3) vs 6.8 
(5.8–7.8) ng/mL], IL6 [6.2 (1.0–10.3) vs 1.3 (1.0–2.0) pg/
mL] and TNFα [5.9 (2.9–11.8) vs 1.6 (1.3–1.8) pg/mL], but 
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Introduction
The accelerated development of atherosclerosis is one of 
the main causes of precocious cardiovascular morbidity 
and mortality in dialysis patients with chronic kidney dis-
ease (CKD) [1]. It can be explained by the co-occurrence 
of classic cardiovascular risk factors (age, sex, hyperten-
sion, lipid disorders, diabetes or obesity) and the so-called 
uraemia-specific risk factors, which include CKD-MBD 
(chronic kidney disease—mineral and bone disorders), 
oxidative stress, accumulation of advanced glycation end 
products (AGEs), uraemic retention solutes (e.g. guanidine, 
asymmetric dimethylarginine (ADMA), p-cresol, indoxyl 
sulphate), as well as low-grade chronic systemic inflamma-
tion (microinflammation) [2–5].
The pathogenesis of chronic inflammation in haemodi-
alysis (HD) patients is complex and not entirely explained. 
It is closely related to atherosclerosis by a bidirectional 
association. Inflammation accelerates the progress of ath-
erosclerosis, and during atherogenesis development, an 
activation of monocytes and macrophages that secrete 
pro-inflammatory cytokines (e.g. TNFα) and chemokines 
occurs. In addition, visceral adipose tissue (the sources of 
pro-inflammatory cytokines) in patients with abdominal 
obesity, contact with blood by the dialyser membrane and 
probably increased intestinal permeability are contributing 
to increased inflammatory state [6].
During the last few years, the importance of intestinal 
microflora contributing to the development of autoimmune 
diseases, hormonal metabolism and systemic inflamma-
tion was raised [7, 8]. Impaired structure and function of 
the intestinal barrier related to dysbiosis may increase the 
penetration of bacteria-derived toxins (including lipopoly-
saccharides), or even viable bacteria into the blood. This 
mechanism can induce systemic inflammation [8, 9]. Accu-
mulation of uraemic toxins and metabolic disorders in 
CKD patients may influence the composition of intestinal 
flora and promote gut permeability. That may lead to deple-
tion of immune system mechanisms and finally to the state 
of immunodeficiency and chronic systemic inflammation; 
however, the data supporting this hypothesis are limited 
[6]. Wang et al. [10] found the evidence for intestinal flora 
translocation (bacterial ribosomal DNA in blood) in six 
CKD stage 5 patients. The presence of bacterial DNA was 
also associated with significantly higher levels of highly 
sensitive CRP, IL6 and d-lactates [11].
Recently zonulin, a new marker potentially useful for 
the evaluation of the permeability of intestinal wall, was 
described [12]. Zonulin is a protein (molecular weight of 
47 kDa), HP2 gene product (which simultaneously encodes 
haptoglobin), which interacts with intercellular connections 
(Zona occludens) [13]. Increased concentration of zonulin 
was observed in patients with sepsis [14], obesity [7], type 
2 diabetes [15] and autoimmune diseases [16]. It has not 
been established whether synthesis of zonulin is altered in 
CKD patients.
Additionally, measurement of d-lactate (a product of 
anaerobic metabolism from intestinal bacteria) concen-
tration in the circulation may reflect colonic absorption 
of bacterial metabolism products. d-lactate and bacterial 
endotoxins are considered primarily as markers of colon 
absorption, partially reflecting the permeability of the intes-
tinal wall [17, 18].
The aim of this study was to evaluate the association 
between markers of intestinal permeability and systemic 
inflammation in haemodialysis patients.
Subjects and methods
One hundred and fifty (N = 150) stable, prevalent HD 
patients (92 men and 58 women) were enrolled into the 
study. Only patients on morning dialysis sessions were 
included due to requirement of morning blood samples col-
lection (after overnight fast). Patients with previous history 
of gastrointestinal diseases, receiving immunosuppressive 
medication, during hospitalization and on HD therapy for 
less than 6 months were excluded (Fig. 1). The study pro-
tocol was accepted by the Bioethical Committee of Medi-
cal University of Silesia in Katowice (KNW-2-015/N/3/K), 
and each patient gave informed consent for participation 
in the study. The study protocol neither included training 
with a nutritionist nor interfered with previous nutrition 
recommendations.
All HD patients were dialysed 3 times per week for 
3.5–5 h (11.7 ± 0.9 h weekly) using low-flux dialys-
ers with polyethersulphone (PES) or polysulphone (PSU) 
membranes (area range 1.5–2.0 m2), with blood flow rates 
from 200 to 250 ml/min and dialysate flow rate 500 ml/
min. Patient characteristics including CKD causes, duration 
of HD therapy and Kt/V are given in Table 1.
Thirty subjects (9 women and 21 men) without concomi-
tant diseases: 9 obese and 21 normal weight, served as a con-
trol group. The exclusion criteria included acute or chronic 
diseases, any drug use, including oral contraceptive agents, 
body mass changes exceeding more than 3 kg during preced-
ing 6 months, cigarette smoking, drinking more than three 
drinks per week, endocrine disorders: hyper- and hypothy-
roidism, Cushing’s syndrome, polycystic ovary syndrome.
The study protocol assumed a single withdrawal of an 
additional blood sample, while performing routine tests 
(blood count, serum urea, calcium, phosphate, sodium, 
potassium), before the midweek HD session after overnight 
fasting. Only patients on morning haemodialysis sessions 
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were recruited. Also in the control group, blood samples 
were obtained in the morning after overnight fast.
Measurements
Plasma concentrations of zonulin (Immundiagnostik 
AG, Bensheim, Germany) haptoglobin (AssayPro, Saint 
Charles, Mo, U.S.), TNFα and IL6 (R&D Systems, Min-
nesota, MN, U.S.), d-lactates (Uscn Life Sciences Inc., 
Wuhan, PRC) and bacterial lipopolysaccharides (Uscn Life 
Sciences Inc., Wuhan, PRC) were assessed by ELISA using 
commercially available kits. The intra-assay and inter-assay 
coefficients of variability were as follows: <5 and <8.5% 
(zonulin), <4.9 and <7.5% (haptoglobin), <7.3 and <4.3% 
(TNFα), <7.2 and <7.8% (IL6), <8 and <10% (d-lactates), 
<10 and <12% (lipopolysaccharides).
Serum hsCRP was assessed by immunoturbidimetric 
method (DRG Instruments GmbH for Hybrid XL, Mar-
burg, Germany) with inter-assay precision <4.8%.
Statistical analysis
Statistical analysis was performed with STATISTICA 10.0 
PL StatSoft, Inc. software (www.statsoft.com). The nor-
mality of quantitative variables distribution was checked by 
Shapiro–Wilk test. Results are given as mean values with 
standard deviation or 95% confidence intervals (95% CI) 
or medians with interquartile range (variables with skewed 
distribution). Study population was divided in tertiles based 
on plasma concentration of zonulin, lipopolysaccharides 
and d-lactates. For comparison of groups (HD patients and 
controls, and subgroups), we used the Chi-square test (qual-
itative variables), and ANOVA or Kruskal–Wallis one-way 
analysis of variance by ranks followed by Mann–Whitney 
U test (quantitative variables). Correlation coefficient was 
calculated according to Spearman.




One hundred and fifty haemodialysis patients were 
included in the study (more than two-thirds of them were 
men). The mean duration of dialysis time was 4 years. 
Average BMI was 26 kg/m2, and 18 (12%) patients met the 
criteria for obesity. Causes of CKD were typical; the most 
common cause was diabetes, then glomerulonephritis and 
finally, hypertensive nephropathy (Table 1). The majority 
of patients were suffering from arterial hypertension, more 
than half of them from coronary disease, and one-third 
from diabetes. Dozens of patients having prior stroke and 
a similar group had a history of past kidney transplantation. 
Half of the patients took anti-platelet agents and over one-
third statins. Oral phosphorous binders were prescribed for 
the majority of the patients (n = 129) (Table 1).
The average value of haemoglobin (10.8 g/dL) sug-
gested effective treatment for patients with anaemia. The 
mean serum concentration of total and LDL cholesterol 
was within the normal range, while the average serum 
HDL concentration was low. Triglyceride concentration 
exceeded the upper limit; typical for CKD stage 5 cal-
cium–phosphate disturbances with secondary hyperpar-
athyroidism were observed. Inflammatory markers (serum 
hsCRP and plasma TNFα) were slightly elevated (Table 2). 
An increased hsCRP level (over 3 mg/dL) was found in 
Fig. 1  Study flow chart
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over 70% of patients. The levels of zonulin (Fig. 2), hsCRP, 
IL6 and TNFα were significantly increased in relation to 
values in control subjects (Table 2). The levels of hapto-
globin, LPS and d-lactates were similar in HD and controls.
Zonulin level variability was not explained by residual 
diuresis, Kt/V and urea reduction ratio.
Subgroups analysis
The zonulin tertiles subgroups of HD patients differ in 
respect of hsCRP and TNFα, but had similar levels of 
d-lactates, LPS and haptoglobin. Similar analysis for LPS 
tertiles showed increasing IL6 levels in the subsequent 
Table 1  Demographic and 
clinical characteristics of 150 
haemodialysis patients and 30 
control subjects (mean and 95% 
CI)
NA not applicable
* Percentage of patients with diabetes
^ Mean value from last 6 months
Haemodialysis patients (N = 150) Control subjects (N = 30)
Age (years) 62 (59–64) 53 (49–57)
Gender (male/female) 92/58 21/9
Body mass index (kg/m2) 26.1 (25.2–26.9) 26.5 (24.8–28.3)
Obesity (BMI ≥ 30 kg/m2) (n/ %) 28/18.7 9/30.0




Autosomal dominant polycystic  
kidney disease (ADPKD)
10/6.7 NA
Ischaemic nephropathy 2/1.3 NA
Glomerulonephritis 24/16.0 NA
Interstitial nephritis 13/8.5 NA
Other or unknown 34/22.7 NA
Time on dialysis (months) 48 (41–56) NA
Kt/V (per HD session)^ 1.05 (1.01–1.08) NA




Coronary artery disease 83/55.3 0
Stroke 12/8.0 0
Past kidney transplantation 11/7.3 0
Pharmacotherapy (n/%)
Antihypertensive 136/90.7 0
No. of antihypertensive drugs (n) 2.0 (1.8–2.2) 0





Oral phosphorous binders 129/86.0 0
Carbonate calcium dose (g/day) 3.8 (3.4–4.3) 0
Sevelamer hydrochloride 4/2.6 0
Cinacalcet 17/11.3 0
Cinacalcet dose (mg/day) 79 (60–98)
Alfacalcidol 31/20.7 0
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tertiles (Fig. 3). In addition, d-lactates tertiles differed in 
respect of IL6 and haptoglobin, but not LPS and zonulin 
levels (Table 3).
Correlations between LPS, d‑lactates and zonulin, 
and inflammatory markers
There was a stronger correlation between plasma concen-
trations of LPS and IL6 (R = 0.241; p = 0.003) than with 
serum hsCRP level (R = 0.153; p = 0.06) (Fig. 4). No 
association with TNFα was found (R = 0.101; p = 0.22). 
The levels of d-lactates were weakly associated with IL6 
(R = 0.175; p = 0.03), but neither with hsCRP (R = −0.022; 
p = 0.78) nor with TNFα (R = −0.139; p = 0.09).
There was a borderline correlation between plasma 
zonulin and serum hsCRP (R = 0.159; p = 0.07). No cor-
relation with plasma IL6 (R = 0.118; p = 0.15), TNFα 
(R = 0.114; p = 0.17), LPS (R = 0.019; p = 0.82) and 
d-lactates (R = −0.083; p = 0.31) was found.
The plasma levels of haptoglobin were weakly related 
to those of zonulin (R = 0.138; p = 0.09) and d-lactates 
(R = 0.186; p = 0.02).
Table 2  Biochemical 
characteristics and the study 
parameters
ND not determined
Mean and 95% CI or * Median (25–75 percentile)
^ Mean value from last 6 months
Haemodialysis patients [N= Control subjects [N = 30] p
Haemoglobin (g/dL)^ 10.8 (10.6–11.0) 13.8 (11.2–14.9) <0.01
Total cholesterol (mg/dL) 169 (160–178) 198 (183–214) <0.05
LDL cholesterol (mg/dL) 90 (84–95) 131 (117–146) <0.05
HDL cholesterol (mg/dL) 28 (26–29) 57 (50–64) <0.01
Triglycerides (mg/dL) 169 (160–178) 114 (95–133) <0.05
Calcium (mg/dL)^ 8.57 (8.44–8.70) ND –
Phosphorous (mg/dL)^ 5.77 (5.52–6.02) ND –
Parathyroid hormone (pg/mL) 449 (380–519) ND –
hsCRP (mg/L)* 4.82 (2.33–11.60) 1.71 (0.87–3.19) <0.05
Interleukin 6 (pg/mL)* 6.20 (1.01–10.32) 1.34 (0.99–1.97) <0.05
Tumour necrosis factor-α (pg/mL)* 5.94 (2.93–11.80) 1.61 (1.31–1.85) <0.01
Bacterial lipopolysaccharides (ng/mL) 27.7 (22.1–36.9) 28.1 (16.6–57.6) 0.72
d-lactates (µg/mL)* 1.47 (0.94–2.34) 1.55 (1.35–1.77) 0.63
Zonulin (ng/mL) 11.6 (10.9–12.3) 6.8 (5.8–7.8) <0.01
Haptoglobin (µg/mL)* 1.37 (0.82–2.03) 1.39 (0.98–1.72) 0.87
Fig. 2  Plasma zonulin concentration in 150 haemodialysis patients 
and 30 control subjects
Fig. 3  Plasma interleukin 6 concentration in subsequent d-lactates 
concentration tertiles
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Table 3  Biochemical characteristics and the study parameters in tertile subgroups of zonulin, bacterial lipopolysaccharides and d-lactates
Zonulin (ng/mL) ANOVA/ 
Kruskal–Wallis
Low tertile <9.8 Medium tertile High tertile >13.1
Haemoglobin (g/dL) 10.6 (10.3–10.9) 10.8 (10.5–11.2) 10.9 (10.5–11.3) p = 0.43
Total cholesterol (mg/dL) 169 (155–183) 161 (146–176) 177 (161–193) p = 0.32
LDL cholesterol (mg/dL) 89 (80–99) 85 (75–94) 95 (84–106) p = 0.35
HDL cholesterol (mg/dL) 28 (26–30) 28 (26–31) 27 (24–30) p = 0.72
Triglycerides (mg/dL) 158 (134–182) 158 (120–196) 162 (134–190) p = 0.97
hsCRP (mg/L)* 3.96 (1.58–10.32) 4.04 (2.20–8.78) 5.76 (3.58–13.20)^ p = 0.07
Interleukin 6 (pg/mL)* 6.39 (1.01–9.66) 4.08 (0.78–9.70) 8.35 (1.28–11.31) p = 0.12
Tumour necrosis factor-α (pg/mL)* 4.41 (2.36–8.26) 7.07 (3.12–15.60)^ 7.01 (3.16–11.80)^ p = 0.04
Bacterial lipopolysaccharides (ng/mL)* 26.9 (22.2–37.0) 28.5 (21.8–35.6) 27.0 (22.9–37.3) p = 0.98
d-Lactates (µg/mL)* 1.77 (0.96–2.62) 1.29 (0.91–2.21) 1.42 (0.98–2.30) p = 0.23
Haptoglobin (µg/mL)* 1.37 (0.74–1.91) 1.27 (0.84–2.36) 1.64 (0.91–2.30) p = 0.54
Bacterial lipopolysaccharides (ng/mL)
Low tertile <24.1 Medium tertile High tertile >32.6
Haemoglobin (g/dL) 10.6 (10.3–10.9) 10.9 (10.6–11.2) 10.9 (10.4–11.3) p = 0.47
Total cholesterol (mg/dL) 171 (153–188) 176 (163–191) 159 (146–173) p = 0.26
LDL cholesterol (mg/dL) 87 (76–97) 95 (86–104) 87 (77–98) p = 0.41
HDL cholesterol (mg/dL) 27 (25–29) 29 (26–31) 27 (25–30) p = 0.65
Triglycerides (mg/dL) 178 (137–219) 153 (129–177) 146 (123–170) p = 0.29
hsCRP (mg/L)* 3.73 (1.80–11.04) 4.84 (3.42–9.08) 5.48 (2.58–15.92) p = 0.21
Interleukin 6 (pg/mL) 3.48 (0.78–8.38) 6.29 (1.20–9.52) 9.11 (1.09–11.80)# p = 0.02
Tumour necrosis factor-α (pg/mL)* 4.94 (2.31–10.10) 6.46 (3.06–12.30) 8.26 (3.15–12.90) p = 0.35
d-Lactates (µg/mL)* 1.65 (0.97–2.38) 1.33 (0.95–2.34) 1.47 (0.94–2.21) p = 0.70
Haptoglobin (µg/mL)* 1.43 (0.84–2.36) 1.33 (0.83–2.30) 1.37 (0.73–1.92) p = 0.63
Zonulin (ng/mL) 10.8 (9.7–11.9) 12.2 (11.2–13.2) 11.8 (10.1–13.4) p = 0.24
d-Lactates (µg/mL)
Low tertile <1.14 Medium tertile High tertile >2.0
Haemoglobin (g/dL) 10.7 (10.4–11.1) 10.7 (10.4–11.1) 10.9 (10.5–11.2) p = 0.80
Total cholesterol (mg/dL) 165 (153–177) 170 (153–186) 173 (156–189) p = 0.76
LDL cholesterol (mg/dL) 89 (80–98) 85 (76–95) 94 (83–106) p = 0.44
HDL cholesterol (mg/dL) 28 (25–30) 28 (25–30) 27 (25–30) p = 0.98
Triglycerides (mg/dL) 150 (126–174) 172 (137–208) 156 (124–187) p = 0.57
hsCRP (mg/L)* 4.84 (2.58–12.60) 5.20 (2.61–10.32) 3.87 (2.15–11.04) p = 0.70
Interleukin 6 (pg/mL)* 2.78 (0.86–9.66) 6.54 (0.68–10.33) 8.27 (1.95–10.80)^ p = 0.04
Tumour necrosis factor-α (pg/mL)* 6.33 (3.15–15.63) 7.07 (2.48–12.20) 4.68 (2.59–10.20) p = 0.15
Bacterial lipopolysaccharides (ng/mL)* 27.5 (21.4–37.6) 27.7 (23.3–36.6) 28.0 (21.3–34.4) p = 0.88
Haptoglobin (µg/mL)* 1.00 (0.71–1.73) 1.64 (1.03–2.33)^ 1.39 (0.89–2.38)^ p = 0.02
Zonulin (ng/mL) 11.4 (10.4–12.3) 12.7 (11.1–14.4) 10.7 (9.6–11.8) p = 0.12
Mean and 95% CI or * median (25–75 percentile)
^ p   < 0.05; # p < 0.01 versus first tertile
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Multiple regression models
In multiple regression models including plasma concentra-
tions of zonulin, LPS and d-lactates, both serum CRP and 
plasma IL6, but not plasma TNFα variability was explained 
only by LPS (β = 0.143; p = 0.08 and β = 0.171; p = 0.04, 
respectively).
Discussion
The levels of zonulin, hsCRP, IL6 and TNFα were sig-
nificantly higher in HD patients, while the levels of hap-
toglobin, LPS and d-lactates were similar in both study 
groups. Additionally, a weak association between plasma 
levels of IL6 and d-lactate as well as LPS were observed, 
while in multiple regression models, serum hsCRP and 
plasma IL6 variability were explained by LPS, only.
Moderate increase of circulating inflammatory mark-
ers (CRP, IL6 and TNFα) is typical for CKD patients [4, 
5]. In addition, the relationship between systemic inflam-
mation in CKD patients and the severity of endotoxaemia 
was reported [19]. Moreover, in animals with experimen-
tally induced CKD, a bacterial DNA was detected in blood, 
spleen, lymph nodes and the liver [20]. The most likely 
source of bacteria is the gut microflora. In CKD, impaired 
intestinal epithelium cellular tight junctions, which allow 
the passage of endotoxins and bacteria into circulation, 
were observed [21, 22]. In addition, an altered composition 
of the intestinal microflora of CKD patients was described. 
This change can be explained by uraemia and addition-
ally by specific diet and medications used in those patients 
[10]. However, in our study despite higher zonulin levels 
in the circulation of HD patients, suggesting increased gut 
permeability, similar concentrations of LPS and d-lactates 
were found. In addition, similar concentrations of LPS 
were showed in zonulin tertiles. These data do not confirm 
significant endotoxaemia in the majority of HD patients 
without gastrointestinal diseases and raise the uncertainty 
concerning zonulin as the marker of gut permeability in 
HD. It should be noted that until now, plasma zonulin (pre-
haptoglobin-2) concentration has not been evaluated in HD 
patients. Our study shows elevated plasma levels of zonulin 
in these patients even after comparison with obese subjects 
[8.2 (7.1–8.4) ng/mL] [7]. The cause of increased zonulin 
level in HD is unclear, also taking into account the lack 
of elevation of plasma haptoglobin (encoded by the same 
gene as zonulin). Perhaps increased plasma zonulin levels 
in HD result from decreased degradation/elimination by the 
kidneys.
One of the examined parameters was plasma level of 
d-lactic acid, a surrogate marker of colon bacteria over-
growth. d-lactic acid exists as two stereoisomers: right-
handed (d) and left-handed (l). Both isomers, as a result of 
the action of a specific lactate dehydrogenase (l and d) (via 
pyruvate conversion), d- or l-lactic acid molecule is pro-
duced. In human cells, activity of d-lactate dehydrogenase 
is not observed, and naturally, only the l-form of lactic acid 
occurs. However, d-lactic acid can be present in the blood 
stream and reflect exogenous origin or be the result of 
methylglyoxal metabolism. Methylglyoxal may be derived 
from carbohydrates, fatty acid or amino acids transforma-
tion. It is a toxic compound and therefore, via glyoxalase 
1 and glyoxalase 2, is converted to d-lactate. Furthermore, 
d-lactates can be derived from enteric bacterial fermenta-
tion predominantly of Lactobacillus and Bifidobacteria 
[23].
Increased plasma concentration of d-lactates may occur 
in the case of sugar overabundance in the diet, short bowel 
syndrome, as well as microbial proliferation and excessive 
Fig. 4  Correlations between plasma concentration of LPS and 
inflammatory markers: a IL6 (R = 0.241; p = 0.003) and b serum 
hsCRP level (R = 0.153; p = 0.06)
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fermentation [23]. It is not clear whether increased intes-
tinal permeability can be accompanied by progression of 
kidney disease or can be due to influence of uraemic tox-
ins on the intestinal wall. Some studies indicate the role of 
urea in this process, but it does not seem to be a key ele-
ment in the development of chronic microinflammation. 
Considering the role of intestinal microflora in the develop-
ment of autoimmune diseases and systemic inflammation 
shown in clinical trials [7], we design this study to explain 
whether chronic inflammation in HD patients corresponds 
to increased intestinal permeability and uraemia-related 
dysbiosis. However, in our study, plasma levels of d-lac-
tates were similar in HD and controls and were weakly 
associated with plasma IL6 concentration. Thus, it seems 
that microbial proliferation and excessive fermentation in 
the colon are only mild factors participating in the systemic 
microinflammation in HD patients.
A weak correlation between levels of IL6 and d-lactates 
and LPS, and the greatest severity of inflammation were 
found in the highest tertile of zonulin, LPS and d-lactates 
concentrations, while in multiple regression models, serum 
hsCRP and plasma IL6 variability were explained by LPS, 
only. This supports the hypothesis that bacteria overgrowth 
in the gut or the increased permeability of intestinal wall 
only in a small part participates to the inflammation devel-
opment in HD patients. In addition, the weakness of these 
relationships confirms that the other well-known mecha-
nisms of systemic inflammation in HD [2] have a predomi-
nant role.
The study has some limitations, including the lack of the 
intestinal microflora analysis and the absence of microflora 
bacterial (ribosomal) DNA identification in plasma sam-
ples, and the lack of performance of intestinal permeability 
tests. Furthermore, the cross-sectional study design pre-
cludes the analysis of cause-and-effect relations.
Conclusion
The weak association between plasma d-lactate, LPS and 
IL6 levels indicates that intestinal flora overgrowth or 
increased intestinal permeability contributes very slightly 
to the chronic inflammation development in HD patients.
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